{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T10:28:40Z","timestamp":1778322520115,"version":"3.51.4"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Persistent inflammatory monoarthritis is defined as inflammation of one joint that continues for longer than 3\u2009months. Most cases remain as nonspecific arthritis after several years. Persistent inflammatory monoarthritis is difficult to diagnose and treat in the early stage because there are no criteria for diagnosis and treatment. We report five seronegative persistent inflammatory monoarthritis cases that affected the left knee, right knee, left knee, left ankle, and right knee. All patients underwent joint punctures; two patients received steroid injections in the affected joint. The bacterial and mycobacterial culture were negative in all patients. Two patients received oral steroids, and two patients were administered nonsteroidal anti-inflammatory drugs; however, their symptoms did not improve, and one patient experienced progression of joint destruction. We investigated the usefulness of biological disease-modifying antirheumatic drugs for the treatment of seronegative persistent inflammatory monoarthritis. We obtained a remarkable improvement effect and prevented the advance of joint destruction.<\/jats:p>","DOI":"10.1093\/mrcr\/rxac063","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T07:58:11Z","timestamp":1660291091000},"page":"307-314","source":"Crossref","is-referenced-by-count":1,"title":["Five cases of seronegative persistent inflammatory monoarthritis improved with biological therapy"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6163-4048","authenticated-orcid":false,"given":"Takuya","family":"Izumiyama","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine , Sendai, Miyagi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine , Sendai, Miyagi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soshi","family":"Hamada","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine , Sendai, Miyagi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Kurishima","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine , Sendai, Miyagi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, Tohoku University Graduate School of Medicine , Sendai, Miyagi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimi","family":"Aizawa","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine , Sendai, Miyagi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"2023010315533169900_R1","first-page":"231","article-title":"Subacute and chronic monoarthritis (excluding shoulder and hip). Criteria, classification, diagnosis and treatment","volume":"23","author":"Lequesne","year":"1971","journal-title":"Rhumatologie"},{"key":"2023010315533169900_R2","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.3899\/jrheum.081217","article-title":"Pattern of joint involvement and other disease characteristics in 634 patients with arthritis of less than 16 weeks\u2019 duration","volume":"36","author":"Mjaavatten","year":"2009","journal-title":"J Rheumatol"},{"key":"2023010315533169900_R3","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3109\/03009748309099744","article-title":"Long-term prognosis of monoarthritis. A follow-up study","volume":"12","author":"Kaarela","year":"1983","journal-title":"Scand J Rheumatol"},{"key":"2023010315533169900_R4","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1007\/s10067-012-2104-3","article-title":"Management of persistent inflammatory large joint monoarthritis","volume":"31","author":"Byng-Maddick","year":"2012","journal-title":"Clin Rheumatol"},{"key":"2023010315533169900_R5","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1093\/rheumatology\/35.11.1096","article-title":"Natural remission in inflammatory polyarthritis: issues of definition and prediction","volume":"35","author":"Harrison","year":"1996","journal-title":"Br J Rheumatol"},{"key":"2023010315533169900_R6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/rheumatology\/32.2.97","article-title":"Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic","volume":"32","author":"Tunn","year":"1993","journal-title":"Br J Rheumatol"},{"key":"2023010315533169900_R7","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2023010315533169900_R8","first-page":"37","article-title":"Does early seronegative arthritis develop into rheumatoid arthritis? A 10-year observational study","volume":"37","author":"Paalanen","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2023010315533169900_R9","doi-asserted-by":"publisher","first-page":"SI23","DOI":"10.1093\/rheumatology\/keab515","article-title":"MRI detected synovitis of the small joints predicts rheumatoid arthritis development in large joint undifferentiated inflammatory arthritis","volume":"61","author":"Sidhu","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2023010315533169900_R10","first-page":"S12","article-title":"Undifferentiated arthritis\u2014disease course assessed in several inception cohorts","volume":"22","author":"Verpoort","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"2023010315533169900_R11","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1136\/annrheumdis-2016-210602","article-title":"2016 update of the EULAR recommendations for the management of early arthritis","volume":"76","author":"Combe","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023010315533169900_R12","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023010315533169900_R13","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1186\/ar1688","article-title":"The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis","volume":"7","author":"Ruderman","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"2023010315533169900_R14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/annrheumdis-2013-203843","article-title":"Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial","volume":"73","author":"Schiff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2023010315533169900_R15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052871","article-title":"Inflammation and bone metabolism in rheumatoid arthritis: molecular mechanisms of joint destruction and pharmacological treatments","volume":"23","author":"Maeda","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2023010315533169900_R16","first-page":"2351","article-title":"Outcome of early monoarthritis: a followup study","volume":"34","author":"Binard","year":"2007","journal-title":"J Rheumatol"},{"key":"2023010315533169900_R17","doi-asserted-by":"publisher","first-page":"264","DOI":"10.5152\/eurjrheum.2017.17011","article-title":"Case series: monoarticular rheumatoid arthritis","volume":"4","author":"Sarazin","year":"2017","journal-title":"Eur J Rheumatol"},{"key":"2023010315533169900_R18","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/art.24827","article-title":"Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis","volume":"61","author":"Aggarwal","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2023010315533169900_R19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/sarh.2002.37215","article-title":"New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis","volume":"32","author":"Hochberg","year":"2002","journal-title":"Semin Arthritis Rheum"},{"key":"2023010315533169900_R20","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1136\/ard.2007.084269","article-title":"Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis?","volume":"67","author":"Saleem","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2023010315533169900_R21","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1136\/ard.2009.119016","article-title":"Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)","volume":"69","author":"Emery","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2023010315533169900_R22","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s10067-018-4105-3","article-title":"Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors","volume":"37","author":"Tymms","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2023010315533169900_R23","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1056\/NEJMoa035075","article-title":"Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig","volume":"349","author":"Kremer","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxac063\/45616601\/rxac063.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/7\/1\/307\/48482471\/rxac063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/7\/1\/307\/48482471\/rxac063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T15:57:22Z","timestamp":1672761442000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/7\/1\/307\/6662543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,8,12]]},"published-print":{"date-parts":[[2023,1,3]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxac063","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,8,12]]}}}